PL372228A1 - Sposób leczenia i profilaktyki utraty masy kostnej - Google Patents

Sposób leczenia i profilaktyki utraty masy kostnej

Info

Publication number
PL372228A1
PL372228A1 PL03372228A PL37222803A PL372228A1 PL 372228 A1 PL372228 A1 PL 372228A1 PL 03372228 A PL03372228 A PL 03372228A PL 37222803 A PL37222803 A PL 37222803A PL 372228 A1 PL372228 A1 PL 372228A1
Authority
PL
Poland
Prior art keywords
bone
treating
bone loss
preventing bone
methods
Prior art date
Application number
PL03372228A
Other languages
English (en)
Inventor
John David Allard
Robert Frederick Klein
Gary Allen Peltz
Original Assignee
F.Hoffmann-La Roche Ag
The Government Of The United States
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag, The Government Of The United States, Oregon Health & Science University filed Critical F.Hoffmann-La Roche Ag
Publication of PL372228A1 publication Critical patent/PL372228A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
PL03372228A 2002-02-08 2003-02-03 Sposób leczenia i profilaktyki utraty masy kostnej PL372228A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35525502P 2002-02-08 2002-02-08

Publications (1)

Publication Number Publication Date
PL372228A1 true PL372228A1 (pl) 2005-07-11

Family

ID=27734489

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372228A PL372228A1 (pl) 2002-02-08 2003-02-03 Sposób leczenia i profilaktyki utraty masy kostnej

Country Status (15)

Country Link
US (2) US20030175680A1 (pl)
EP (3) EP1666883A1 (pl)
JP (1) JP2005531498A (pl)
KR (2) KR100653017B1 (pl)
CN (3) CN100410388C (pl)
AT (1) ATE385835T1 (pl)
AU (1) AU2003206822C1 (pl)
BR (1) BR0307522A (pl)
CA (2) CA2697599A1 (pl)
DE (1) DE60319156T2 (pl)
ES (1) ES2299923T3 (pl)
MX (1) MXPA04007611A (pl)
PL (1) PL372228A1 (pl)
RU (3) RU2319483C2 (pl)
WO (1) WO2003066048A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) * 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
WO2002096284A1 (en) 2001-05-25 2002-12-05 Imaging Therapeutics, Inc. Methods to diagnose treat and prevent bone loss
US8965075B2 (en) 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
US7840247B2 (en) 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
US7664298B2 (en) 2003-03-25 2010-02-16 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
GB0410103D0 (en) * 2004-05-06 2004-06-09 Biolipox Ab New method
WO2005123130A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
CA2580726A1 (en) 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
US20070036770A1 (en) * 2005-08-12 2007-02-15 Wagner Darrell O Biologic device for regulation of gene expression and method therefor
WO2007022427A2 (en) 2005-08-18 2007-02-22 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
US20090247634A1 (en) * 2006-06-27 2009-10-01 Hans-Erik Claesson Methods for identifying modulators of eoxin formation
US20080076836A1 (en) * 2006-09-01 2008-03-27 Cardiac Pacemakers, Inc Method and apparatus for using light to enhance cell growth and survival
WO2008034101A2 (en) * 2006-09-15 2008-03-20 Imaging Therapeutics, Inc. Method and system for providing fracture/no fracture classification
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
EP2142924A2 (en) * 2007-04-26 2010-01-13 President And Fellows Of Harvard College Assays for the identification of compounds that modulate bone formation and mineralization
WO2009105723A2 (en) * 2008-02-22 2009-08-27 Accelalox, Inc. Novel methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage
US20110136728A1 (en) * 2009-12-09 2011-06-09 Patricia Grasso Methods of increasing bone formation using leptin-related peptides
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
CN102138961A (zh) * 2010-02-02 2011-08-03 北京绿色金可生物技术股份有限公司 黑豆皮提取物在预防和治疗骨关节炎的产品中的应用
KR101474053B1 (ko) 2011-04-08 2014-12-19 울산대학교 산학협력단 골다공증 또는 골다공성 골절 발생 위험도 예측용 다형성 마커
RU2517037C1 (ru) * 2013-02-08 2014-05-27 Евгений Викторович Ларионов Способ получения костного минерального компонента и костный минеральный компонент для замещения и восстановления дефектов костной ткани
EP3036226B1 (en) 2013-08-22 2020-01-08 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
EP3159003A3 (en) * 2015-10-23 2017-07-19 Universiti Putra Malaysia Composition for enhancing bone growth, preventing bone resorption disorders and for joint health
CN106405064B (zh) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 一种40岁以上女性骨转换率的评估方法
CN108251454A (zh) * 2017-12-26 2018-07-06 温州医科大学附属第医院 一种脂氧合酶基因修饰间充质干细胞的获取方法及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA838339B (en) * 1982-11-11 1985-06-26 Beecham Group Plc Novel arachidonic acid analogues and pharmaceutical compositions containing them
DE3360677D1 (en) 1982-11-11 1985-10-03 Beecham Group Plc Arachidonic acid analogues, processes for their preparation and their use in medicine
US4623661A (en) * 1985-04-26 1986-11-18 Abbott Laboratories Lipoxygenase inhibiting compounds
US4605669A (en) 1985-04-26 1986-08-12 Abbott Laboratories Lipoxygenase inhibiting naphthohydroxamic acids
US4761403A (en) * 1986-04-09 1988-08-02 Abbott Laboratories Lipoxygenase inhibiting compounds
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
CA2087836A1 (en) * 1990-07-25 1992-01-26 Dee W. Brooks Acetylene derivatives having lipoxygenase inhibitory activity
US5478579A (en) * 1991-02-06 1995-12-26 Biodyn Medical Research, Inc. Method for treatment of osteoporosis
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5641747A (en) * 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US5620997A (en) * 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
US5717062A (en) 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
AU6966696A (en) * 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) * 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU1529799A (en) 1997-12-23 1999-07-12 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
WO2001096298A2 (en) 2000-06-14 2001-12-20 Warner-Lambert Company 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase

Also Published As

Publication number Publication date
RU2004127131A (ru) 2005-09-20
JP2005531498A (ja) 2005-10-20
CN1936023A (zh) 2007-03-28
WO2003066048A2 (en) 2003-08-14
RU2358728C2 (ru) 2009-06-20
AU2003206822A1 (en) 2003-09-02
RU2319483C2 (ru) 2008-03-20
CN1630518A (zh) 2005-06-22
KR100653017B1 (ko) 2006-12-01
MXPA04007611A (es) 2005-05-27
EP1666883A1 (en) 2006-06-07
EP1476153A2 (en) 2004-11-17
ATE385835T1 (de) 2008-03-15
CN100410388C (zh) 2008-08-13
KR20060029705A (ko) 2006-04-06
DE60319156T2 (de) 2009-01-29
AU2003206822B2 (en) 2008-05-29
CN1287789C (zh) 2006-12-06
RU2007132977A (ru) 2009-03-10
KR20040111353A (ko) 2004-12-31
US20060079488A1 (en) 2006-04-13
EP1634618B1 (en) 2008-02-13
ES2299923T3 (es) 2008-06-01
BR0307522A (pt) 2004-12-07
KR100589819B1 (ko) 2006-06-14
CA2474431A1 (en) 2003-08-14
DE60319156D1 (de) 2008-03-27
EP1634618A1 (en) 2006-03-15
US20030175680A1 (en) 2003-09-18
AU2003206822C1 (en) 2009-01-22
RU2007132981A (ru) 2009-03-10
CA2697599A1 (en) 2003-08-14
CN1896270A (zh) 2007-01-17
WO2003066048A3 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
PL372228A1 (pl) Sposób leczenia i profilaktyki utraty masy kostnej
HK1127545A1 (en) Methods for treating tweak-related conditions tweak
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
MX2010002971A (es) Metodo para inhibir la reabsorcion del hueso.
MX2008009579A (es) Metodo para el tratamiento de dolor neuropatico.
WO2007022427A3 (en) Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
PT1796660T (pt) Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta
SI1880744T1 (sl) Bifosfonske kisline za zdravljenje in prepreäśevanje osteoporoze
CY1106915T1 (el) Συνδυασμοι διαχωριστη(ων) χολικου οξεος και αναστολεα(ων) απορροφησης στερολης και θεραπειες για αγγειακες ενδειξεις
IL186369A0 (en) Method of treating or preventing bone deterioration or osteoporosis
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
DE69905488D1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
DE60022885D1 (de) Verfahren zur mürbmachen von fleisch
UA84723C2 (ru) Десульфурационный агент для стали и способ десульфуризации стали
EP1755637B8 (en) Methods for preventing or treating bone disorders
WO2003102158A3 (en) Methods for increasing bone density
BR0317491A (pt) Método de usar um inibidor de cox-2 e um inibidor de topoisomerase ii como uma terapia de combinação no tratamento de neoplasia
PT1401455E (pt) Utilizacao de um adsorvente de fosfato para combater doencas vasculares
MXPA03000313A (es) Uso de fosfato de estramustina en el tratamiento de metastasis osea.
GB2392838B (en) Calcium L-threonate for preventing or treating cartilage related diseases
AU2003297281A8 (en) Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors
EP1300159A4 (en) REMEDIES FOR CANCER
AU2003282035A1 (en) Modulation of s6 kinase activity for the treatment of obestiy
HK1059391A1 (en) Use of quetiapine for the treatment of cocaine dependence
MY144317A (en) Treatment of polysilazane waste

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)